Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma (GBM).
Embryonal tumor with multilayered rosettes (ETMR) is a rare and aggressive embryonal brain tumor that solely occurs in infants and young children and has only recently been recognized as a separate brain tumor entity...
Day One Biopharmaceuticals announced the recently completed submission of the rolling New Drug Application (NDA) to the FDA for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (LGG). The Company anticipates the FDA will file the rolling NDA by mid-November 2023.
With the release of the 2016 edition of the WHO Classification of Central Nervous System Tumors, brain invasion in meningiomas has been added as a stand-alone criterion for atypia and can therefore impact grading and indirectly adjuvant therapy.
Glioblastoma (GBM) is the most common primary malignant brain tumor that nearly always results in a bad prognosis.